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Aims. To determine whether the erythrocyte phosphorylated ribavirin (RBV) level might be a useful index of EVR and risk of
anemia and to determine the optimal dose of RBV in 24 patients with hepatitis C with pegylated interferon and RBV. Methodology.
The RBV level was measured by a high-performance liquid chromatography. Results and Conclusion. In patients aged 50 years or
over, a negative correlation (r =− 0.548, P<. 05) was observed between the RBV level at week 2 and rate of Hb reduction (ΔHb)
at week 4. The ΔHb at week 4 was signiﬁcantly greater in patients with RBV levels of ≥800μM( −25.5 ± 10.1%) than in patients
with RBV levels <800μM( −15.6 ± 7.7%). None of the patients with RBV levels <600μM at week 2 achieved EVR and SVR. Thus
the optimal levels of erythrocyte phosphorylated RBV at week 2 of therapy in order to achieve EVR without anemia seemed to be
600–800μM.
1.Introduction
The combination therapy with pegylated interferon (PEG-
IFN) and ribavirin (RBV) has come to be established as
the standard treatment for chronic hepatitis C. A sustained
virological response (SVR) has been reported with this
treatment in 30%–50% of patients with HCV genotype 1b
infection, which accounts for 70% of all Japanese patients
with chronic hepatitis C [1]. However, the treatment often
needs to be discontinued, or the dose of RBV changed, in
these patients due to the development of hemolytic anemia.
On the other hand, continuous treatment is important to
obtain SVR with the treatment [2].
RBV is incorporated into the cells via the equilibrative
nucleoside transporter (ENT) and converted to phosphates
within the cells. RBV monophosphate (RMP) and RBV
triphosphate (RTP) are considered to have antiviral activ-
ity [3, 4]. In nucleated cells, the phosphorylated RBV
is subsequently dephosphorylated by the dephosphorylat-
ing enzyme, and RBV is eliminated from the cells via
the ENT. However, in akaryocytes such as erythrocytes,
which lack the dephosphorylating enzyme, accumulation of
phosphorylated RBV occurs, which diminishes the cellular
ATP and alters the cellular characteristics; these changes
in the characteristics of the erythrocytes activate the cell-
elimination activity of the reticuloendothelial system, result-
ing in hemolysis [5, 6].
In this study, with the objective of reducing the adverse
eﬀects and improving the treatment completion rate in
patients receiving combined PEG-IFN and RBV therapy, we
attempted to evaluate whether the erythrocyte phosphory-
lated RBV level might be useful as an index for the rate2 Hepatitis Research and Treatment
of Early Virological Response (EVR) and SVR, the risk of
anemia.
2.MaterialsandMethods
2.1. Subjects. Among the patients with chronic hepatitis C
caused by genotype 1b infection in whom combined PEG-
IFNα2b and RBV therapy was started, 24 patients who
provided written informed consent for participation in this
study were enrolled. The dosage regimen for the combined
PEG-IFN and RBV therapy was determined in accordance
with the standard dosing recommended for Japanese HCV
patients. RBV was started at the initial dose of 600mg/day in
patients with a body weight of ≤60kg, 800mg/day in those
with a body weight of >60kg and ≤80kg, and 1,000mg/day
in those with a body weight of >80kg. In patients with no
cardiovascular disease, the RBV dosage of 600mg/day was
decreased to 400mg/day, and 800mg or 1000mg/day was
reduced to 600mg/day, if hemoglobin (Hb) level decreased
to less than 10g/dL; permanently discontinued the drug if
Hb decreased to less than 8.5g/dL. In those with history
of stable cardiovascular disease, the dosage of RBV was
decreased to 400mg or 600mg if Hb decreased by 2g/dL or
more during any 4-week period; permanently discontinued
thedrugifHbwaslessthan12g/dLafter4weeksofareduced
RBV dosage. The patients were followed up until 48 weeks
after the start of the combined IFN and RBV therapy, and
Hb level and HCV RNA level were examined at week 12 after
the start of treatment.
Serum HCV RNA negativity until 12 week of the
therapy was deﬁned as EVR. Additionally, serum HCV RNA
negativity until 24 weeks after the therapy was completed
and was deﬁned as SVR. This study was performed with the
approval of the hospital research committee, in compliance
with the ethical principles laid out in the Declaration of
Helsinki.
2.2. Measurement of the Erythrocyte Level of Phosphorylated
RBV. Ten-mL samples of venous blood were obtained at
2, 4, and 8 weeks after the start of the therapy, and the
erythrocyte level of phosphorylated RBV was measured by
the HPLC method described by Homma et al. [7]. In this
method, all phosphorylated RBV (RMP, RDP, and RTP) is
converted back to RBV by treatment with an erythrocyte
dephosphorylating enzyme, and the erythrocyte level of
phosphorylated RBV is calculated as the diﬀerence in the
RBV levels measured before and after the enzyme treatment.
2.3. Statistical Analysis. The changes in the Hb level were
analyzed by repeated-measures ANOVA and Dunnett’s test.
The relationships of the RBV level to the risk of anemia and
the drug eﬃcacy were examined by Student’s t-test, Pearson’s
correlation coeﬃcient, χ2-test, and Fisher’s exact probability
test. P<. 05 was regarded as denoting clinical signiﬁcance.
3. Results
3.1. Patient Characteristics and Therapeutic Course. The
subjects comprised 24 patients, and their demographic
Table 1: Baseline characteristics of patients.
Characteristics (n = 24)
Age (years) 59.9 ± 10.3
Sex (M/F) 12/12
Past treatment (Yes/No) 15/9
Body weight (kg) 57.7 ±9.1
Ribavirin (mg/kg/day) 11.7 ±1.5
Hemoglobin (g/dL) 13.6 ±1.3
HCV RNA (KIU/mL)
<100 1
100∼500 3
500∼850 4
850  16
Data are expressed as mean ± S.D. or number of patients
HCV: Hepatitis C virus.
characteristics are indicated in Table 1. The combined PEG-
IFN and RBV therapy needed to be discontinued in 3 of
the 24 patients (12.5%), and the RBV dose needed to be
reduced in 7 of the patients (29.2%) due to the development
of anemia (Hb ≤ 10g/dL). One patient was discontinued
the therapy due to adverse reaction except anemia. However,
the conditions of RBV administration for the initial 4 weeks
were not changed. None of those in whom this therapy
was discontinued achieved EVR. There were no signiﬁcant
diﬀerence in the EVR rates between the subjects in whom
the RBV dose was reduced (72.7%) and those in whom the
therapy continued at the initial dose (64.0%). The dosage of
PEG-IFN was 1.5 ± 0.2μg/kg in accordance with a standard
regimen, and the conditions of IFN administration have not
changed for 48 weeks after the combination therapy was
started in the subjects except for 4 patients who discontinued
the therapy.
3.2. Changes in the Hb Level. T h eH bl e v e l s( 1 1 .0 ±1.3g/dL)
were signiﬁcantly lower at week 4 of therapy as compared
with 13.6 ± 1.3g/dL at the start. In addition, the rate of
Hbreduction[(Hblevel-Hblevelbeforeadministration)/Hb
levelbeforeadministration]atweek4oftherapywas −12.4%
in those aged less than 50 years, whereas it was −21.0% in
those aged 50 years or over (P<. 05).
3.3. Changes in the Erythrocyte Phosphorylated RBV Level.
The phosphorylated RBV and nonphosphorylated RBV
levels in the erythrocytes were 749.3±244.3a n d6 .9±3.6μM
at week 2, 1039.9 ± 239.6a n d8 .4 ± 7.0μMa tw e e k4 ,
and 907.9 ± 292.1a n d8 .9 ± 8.0μM at week 8 of therapy,
respectively; thus, about 99% of the RBV in the erythrocytes
was phosphorylated (Figure 1).
3.4. Relationship between the Erythrocyte Phosphorylated
RBV Level at Week 2 and the Frequency of Anemia. The
relationship between the RBV level at week 2 and the rate
of reduction of the Hb level was examined in the 19 patients
aged 50 years or over. There was a negative correlation (r =
−0.548,P<. 05)betweentheRBVlevelatweek2andtherateHepatitis Research and Treatment 3
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Figure1:Timecourseoferythrocytephosphorylatedribavirincon-
centration after starting PEG-IFNα-2b and ribavirin combination
therapy.
of Hb reduction (ΔHb) at week 4 in the subjects in whom
the dose of RBV did not reduce or the combination therapy
did not discontinue until week 4 (Figure 2). As shown in
Figure 3,theΔHgatweek4wassigniﬁcantlyhigher(P<. 05)
in those with RBV level of ≥800μM( −25.5±10.1%) than in
those with the level of <800μM( −15.6 ±7.7%).
3.5. Relationship between the Erythrocyte Phosphorylated RBV
Level at Week 2 and the EVR. The relationship between
the phosphorylated RBV level at week 2 and the EVR was
evaluated in 20 of the 24 patients (Four cases were excluded
because of the discontinuation of the therapy). The mean
RBV level at week 2 was signiﬁcantly lower (P<. 05) in the
non-EVR patients (634.6 ±236.6μM) than the EVR patients
(889.7 ±210.6μM).
As shown in Table 2, 3 cases with the phosphorylated
RBV level in erythrocytes ≥800μM discontinued the com-
bination therapy prematurely due to anemia, whereas none
of 14 cases with a levels <800μM discontinued prematurely.
There were no EVR or SVR cases (0 of 7 cases) in patients
with erythrocyte phosphorylated RBV levels <600μMa t
week 2, whereas, in those with levels ≥600μM, 11 of 17
cases (64.7%) had EVR and 6 of 17 cases (35.3%) had SVR
(P<. 05).
Five of 7 cases (71.4%) with erythrocyte phosphorylated
RBV level at week 2 of 600–800μM achieved EVR and 3
cases (42.9%) achieved SVR without development of marked
anemia. None of those patients discontinued RBV due to
development of anemia.
4. Discussion
In this study, combined PEG-IFN and RBV therapy needed
to be discontinued, or the RBV dose needed to be reduced,
in about 40% of the study subjects due to the development
of hemolytic anemia (Hb ≤ 10g/dL). None of the patients
in whom the combined PEG-IFN and RBV therapy was
discontinued by Week 12 showed SVR. However, no dif-
ference in the rate of SVR was noted between the subjects
in whom the RBV dose was reduced and those in whom
the treatment could be continued at the initial dose. This
r =− 0.548
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Figure 2: Correlation between 4-week hemoglobin reduction rate
from the baseline and 2-week erythrocyte phosphorylated ribavirin
concentration in patients aged 50 and over. r =− 0.548 (P<. 05).
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Figure 3: Comparison of 4-week hemoglobin reduction rate from
thebaselineofthepatientswith2-weekerythrocytephosphorylated
ribavirinconcentration(<800μM)to4-weekhemoglobinreduction
rate from the baseline of the patients with 2-week erythrocyte
phosphorylated ribavirin concentration(800μM ).
suggests that continuation of the combination therapy was
the most important factor for achieving the desired clinical
outcome. Clinically, the RBV dose reduction is performed
based on the present Hb level. However, it has been noted
that such dose adjustment does not eﬀectively prevent the
progression of anemia; that is, once a decrease of the Hb
level has occurred, it is too late to stop the decline through
RBV dose reduction, presumably because of erythropoietic
delay.
In our subjects, the phosphorylated RBV level reached
a steady-state by 4 weeks of RBV therapy (1040 ± 240μM),
implying gradual accumulation of phosphorylated RBV.
Inoue et al. [8] reported that the erythrocyte phosphorylated
RBV level at the steady-state at week 4 was 1218 ± 234μM
and was well correlated with Hb reduction.4 Hepatitis Research and Treatment
Table 2: Comparisonsof theratein which RBVwas discontinued, therate in which RBVdosage was reduced due todevelopment of anemia,
4-week hemoglobin reduction rate from the baseline, the EVR rate and the SVR rate of the patients with 2-week erythrocyte phosphorylated
RBV concentration <600μM to 600–800μM, and 800μM .
<600μM( n = 7) 600–800μM( n = 7) 800μM  (n = 10)
Rate of RBV discontinuation (%) 0/7 (0) 0/7 (0) 3/10 (30.0)
Rate of RBV reduction (%) 1/7 (14.3) 3/7 (42.9) 3/10 (30.0)
ΔHb by 4 weeks (%) −13.5 ±8.8 −15.7 ±6.5 −23.4 ±11.6
Rate of EVR(%) 0/7 (0) 5/7 (71.4) 6/10 (60.0)
Rate of SVR (%) 0/7 (0) 3/7 (42.6) 3/10 (30.0)
RBV: ribavirin.
ΔHb: 4-week hemoglobin reduction rate from the baseline.
EVR: Early Virological Response; Serum HCV RNA negativity until 12 weeks of therapy.
SVR: Sustained Virological Response; Serum HCV RNA negativity at 24 weeks after completed therapy.
ΔHb is expressed as mean ± S.D.
However, as the Hb level had already decreased sig-
niﬁcantly by week 4, the RBV level at week 4 does not
predict anemia. Therefore, we decided to evaluate whether
the phosphorylated RBV level at week 2 might be useful for
prediction of the subsequent development of anemia.
A close negative correlation was observed between the
erythrocytephosphorylatedRBVlevelatweek2andtheΔHb
at week 4 in patients aged 50 years or over. In general, in
elderly people, the percentage of fat cells in the bone marrow
increases, and the reserve of marrow stem cells decreases
with reduction of the hematopoietic mass and reduction
in the ability for formation of erythroid colony-forming
units [9, 10]. Additionally, RBV is known to be substantially
excreted by kidney, and renal function decreases in elderly
patients. Therefore, RBV accumulation is considered to be
more likely to cause anemia in the elderly, especially due
to the erythropoietic delay and the delay of RBV excretion.
Nomura et al. reported that one of the higher risk of severe
anemia was age higher than about 60 years [11].
InpatientswithRBVlevelof≥800μMatweek2,theΔHb
at week 4 was signiﬁcantly higher, and a higher percentage
of patients needed discontinuation of the RBV due to the
development of anemia. Thus, we recommend that the
erythrocyte phosphorylated RBV level be maintained at a
level of less than 800μM at week 2 for treatment safety.
The plasma RBV level has been reported not to be
correlatedwiththeSVR[12],buttherehavebeenfewreports
on the relationship between the erythrocyte phosphorylated
RBV level and the treatment eﬃcacy. The erythrocyte RBV
level is about 150 times higher than the plasma RBV concen-
tration, and most of the administered RBV is considered to
be secreted into the urine. Of the proportion that remains
in the body, most of it does accumulate as phosphorylated
product within erythrocytes [13]. Furthermore, Homma et
al. reported that little phosphorylated RBV existed in the
plasma [13]. Since RBV taken up by cells is considered to be
phosphorylated, and RMP and RTP are considered to have
antiviral activities, the erythrocyte phosphorylated RBV level
isausefulindexfortheantiviraleﬀectofthedrug.SinceEVR,
deﬁned as a decrease of the HCV RNA level to 1/100 or zero
at week 12 after the start of therapy, has been reported to be
useful as a prognostic factor [14], we focused on not only
SVR but also EVR.
In this study, the erythrocyte phosphorylated RBV level
at week 2 was predictive of the EVR. Moreover, none of the
patients in whom the phosphorylated RBV level at week 2
was <600μM showed both EVR and SVR. Adjustment of
the RBV dose to obtain an erythrocyte phosphorylated RBV
level of ≥600μM at week 2 is considered to be required
to obtain an EVR. It would be necessary to have a large
sample size, study of quality of life, and demonstration
o fb e t t e rE V Ra n dS V Ri nap r o s p e c t i v er a n d o m i z e dt r i a l .
Recently, Fellay et al. reported that genetic variants leading
to inosine triphosphatase (ITPA) deﬁciency protects against
clinically signiﬁcant decline in Hb level induced by HCV
antiviral treatment [15]. We should examine the relation-
ships between ITPA gene variants and RBV-induced anemia
in Japanese populations, and evaluate the usefulness as an
index to reduce the risk of anemia with erythrocyte RBV
level.
5. Conclusion
In this study, the erythrocyte phosphorylated RBV level at
week 2 is proposed as a useful indicator to determine an
optimal dosage of ribavirin in patients with chronic hepatitis
C under treatment with combination therapy with pegylated
interferon and RBV.
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